Home/Filings/4/0001746473-26-000008
4//SEC Filing

Kuo Minnie 4

Accession 0001746473-26-000008

CIK 0001746473other

Filed

Jan 21, 7:00 PM ET

Accepted

Jan 22, 9:38 PM ET

Size

5.6 KB

Accession

0001746473-26-000008

Research Summary

AI-generated summary of this filing

Updated

Pliant Therapeutics (PLRX) COO Minnie Kuo Sells 6,917 Shares

What Happened
Minnie Kuo, Chief Operating Officer of Pliant Therapeutics, reported a sale of 6,917 shares (code S) on January 20, 2026. The weighted average sale price reported is $1.28 per share, for a total value of approximately $8,854. This sale was executed under a nondiscretionary Rule 10b5-1 arrangement to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units (RSUs), so it is a routine tax-withholding sale rather than an open-market discretionary trade.

Key Details

  • Transaction date listed: January 20, 2026 (weighted average sale prices reflect trades from Jan 20–22, 2026).
  • Price: weighted average $1.28 per share (individual trade prices ranged $1.245–$1.33).
  • Shares sold: 6,917; Proceeds ≈ $8,854.
  • Amount owned following the transaction: not provided in the supplied filing details.
  • Footnote: Sale was nondiscretionary under a 10b5-1 plan and executed by a broker on behalf of a group of employees to cover withholding; the filer will provide breakdown of shares sold at each price on request.
  • Timeliness: Filed Jan 22, 2026 for a Jan 20, 2026 transaction — appears timely (not marked late).

Context
Sales to cover tax withholding on vested RSUs are common and typically reflect administrative needs rather than a personal view on the company’s prospects. The 10b5-1 plan and broker-managed execution indicate the sale was pre-arranged and nondiscretionary.

Insider Transaction Report

Form 4
Period: 2026-01-20
Kuo Minnie
Chief Operating Officer
Transactions
  • Sale

    Common Stock

    [F1]
    2026-01-20$1.28/sh6,917$8,85437,806 total
Footnotes (1)
  • [F1]Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
Signature
/s/ Jennifer Woo, attorney-in-fact|2026-01-22

Issuer

PLIANT THERAPEUTICS, INC.

CIK 0001746473

Entity typeother

Related Parties

1
  • filerCIK 0002101360

Filing Metadata

Form type
4
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 9:38 PM ET
Size
5.6 KB